Decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas

Clinical Cancer Research

Volumn 15, Issue 11, 2009, Pages 3881-3888

  Stewart, David J ^a   Issa, Jean Pierre ^a   Kurzrock, Razelle ^a   Nunez, Maria I ^a   Jelinek, Jaroslav ^a   Hong, David ^a   Oki, Yasuhiro ^a   Guo, Zhong ^a   Gupta, Sanjay ^a   Wistuba, Ignacio I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; DNA METHYLTRANSFERASE 1; KI 67 ANTIGEN; PROTEIN P16;

ADULT; AGED; ANEMIA; APOPTOSIS; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CLINICAL TRIAL; CTR 1 ONCOGENE; CYTOTOXICITY; DNA METHYLATION; DRUG EFFECT; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; GENE EXPRESSION; HUMAN; HYPERGLYCEMIA; INFECTION; KIDNEY VEIN THROMBOSIS; LYMPHOMA; MALE; MITOSIS; NEUTROPENIA; ONCOGENE; PERIPHERAL BLOOD MONONUCLEAR CELL; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; SOLID TUMOR; TUMOR NECROSIS;

ADULT; AGED; ANTIMETABOLITES, ANTINEOPLASTIC; APOPTOSIS; AZACITIDINE; BLOOD PRESSURE; CATION TRANSPORT PROTEINS; DNA (CYTOSINE-5-)-METHYLTRANSFERASE; DNA METHYLATION; DNA MODIFICATION METHYLASES; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; IN SITU NICK-END LABELING; KI-67 ANTIGEN; LEUKOCYTES, MONONUCLEAR; LYMPHOMA; MALE; MIDDLE AGED; NEOPLASMS; SEX FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 66649105473     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-2196     Document Type: Article

References (43)

1. Kim JS, Kim H, Shim YM, Han J, Park J, Kim DH. Aberrant methylation of the FHIT gene in chronic smokers with early stage squamous cell carcinoma of the lung. Carcinogenesis 2004;25:2165-2171 (Pubitemid 39534854)
2. Oki Y, Aoki E, Issa JP. Decitabine-bedside to bench. Crit Rev Oncol Hematol 2007;61:140-152 (Pubitemid 46073782)
3. Baylin SB, Herman JG, Graff JR, Vertino PM, Issa JP. Alterations in DNA methylation: a fundamental aspect of neoplasia. Adv Cancer Res 1998;72:141-196
4. Ghoshal K, Bai S. DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 2007;43:395-422. (Pubitemid 47234771)
5. Chekhun VF, Lukyanova NY, Kovalchuk O, Tryndyak VP, Pogribny IP. Epigenetic profiling of multidrug-resistant human MCF-7 breast adenocarcinoma cells reveals novel hyper- and hypomethylated targets. Mol Cancer Ther 2007;6:1089-1098 (Pubitemid 46554580)
6. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31. (Pubitemid 46810280)
7. Stewart DJ, Chiritescu G, Dahrouge S, Banerjee S, Tomiak EM. Chemotherapy dose-response relationships in non-small cell lung cancer and implied resistance mechanisms. Cancer Treat Rev 2007;33:101-137 (Pubitemid 46343105)
8. Plumb JA, Strathdee G, Sludden J, Kaye SB, Brown R. Reversal of drug resistance in human tumor xenografts by 2′-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000;60:6039-6044
9. Shen DW, Su A, Liang XJ, Pai-Panandiker A, Gottesman MM. Reduced expression of small GTPases and hypermethylation of the folate binding protein gene in cisplatin-resistant cells. Br J Cancer 2004;91:270-276 (Pubitemid 39037071)
10. Liang XJ, Shen DW, Gottesman MM. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. J Inorg Biochem 2004;98:1599-1606 (Pubitemid 39349186)
11. Safaei R, Howell SB. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit Rev Oncol Hematol 2005;53:13-23. (Pubitemid 39656107)
12. Holzer AK, Katano K, Klomp LW, Howell SB. Cisplatin rapidly down-regulates its own influx transporter hCTR1 in cultured human ovarian carcinoma cells. Clin Cancer Res 2004;10:6744-6749 (Pubitemid 39346572)
13. Kantarjian HM, O'Brien S, Huang X, et al. Survival advantage with decitabine versus intensive chemotherapy in patients with higher risk myelodysplastic syndrome: comparison with historical experience. Cancer 2007;109:1133-1137 (Pubitemid 46435392)
14. Issa JP, Gharibyan V, Cortes J, et al. Phase II study of low-dose decitabine in patients with chronic myelogenous leukemia resistant to imatinib mesylate. J Clin Oncol 2005;23:3948-3956 (Pubitemid 46218698)
15. Issa JP, Garcia-Manero G, Giles FJ, et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2′- deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004;103:1635-1640 (Pubitemid 38268953)
16. Appleton K, Mackay HJ, Judson I, et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J Clin Oncol 2007;25:4603-4609 (Pubitemid 350035319)
17. Stewart DJ, Donehower RC, Eisenhauer EA, et al. A phase I pharmacokinetic and pharmacodynamic study of the DNA methyltransferase 1 inhibitor MG98 administered twice weekly. Ann Oncol 2003;14:766-774 (Pubitemid 36621778)
18. Ghoshal K, Datta J, Majumder S, et al. 5-Aza-deoxycytidine induces selective degradation of DNA methyltransferase 1 by a proteasomal pathway that requires the KEN box, bromo-adjacent homology domain, and nuclear localization signal. Mol Cell Biol 2005;25:4727-4741 (Pubitemid 40705775)
19. Kantarjian H, Oki Y, Garcia-Manero G, et al. Results of a randomized study of 3 schedules of low-dose decitabine in higher-risk myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 2007;109:52-57 (Pubitemid 46053042)
20. Koshy M, Dorn L, Bressler L, et al. 2-deoxy 5-azacytidine and fetal hemoglobin induction in sickle cell anemia. Blood 2000;96:2379-2384
21. Digel W, Lubbert M. DNA methylation disturbances as novel therapeutic target in lung cancer: preclinical and clinical results. Crit Rev Oncol Hematol 2005;55:1-11. (Pubitemid 40779471)
22. Lutz RJ, Galbraith WM, Dedrick RL, Shrager R, Mellett LB. A model for the kinetics of distribution of actinomycin-D in the beagle dog. J Pharmacol Exp Ther 1977;200:469-478 (Pubitemid 8089835)
23. Suzuki M, Hori K, Abe I, Saito S, Sato H. A new approach to cancer chemotherapy: selective enhancement of tumor blood flow with angiotensin II. J Natl Cancer Inst 1981;67:663-669 (Pubitemid 11050938)
24. Guichard M, Lespinasse F, Trotter M, Durand R, Chaplin D. The effect of hydralazine on blood flow and misonidazole toxicity in human tumour xenografts. Radiother Oncol 1991;20:117-123
25. Raghunand N, Gillies RJ. pH and drug resistance in tumors. Drug Resist Updat 2000;3:39-47.
26. Koukourakis MI, Giatromanolaki A, Sivridis E. Lactate dehydrogenase isoenzymes 1 and 5: differential expression by neoplastic and stromal cel ls in non-small cell lung cancer and other epithelial malignant tumors. Tumour Biol 2003;24:199-202. (Pubitemid 37500569)
27. Kozin SV, Shkarin P, Gerweck LE. The cell transmembrane pH gradient in tumors enhances cytotoxicity of specific weak acid chemotherapeutics. Cancer Res 2001;61:4740-4743 (Pubitemid 32691884)
28. Raghunand N, He X, van Sluis R, et al. Enhancement of chemotherapy by manipulation of tumour pH. Br J Cancer 1999;80:1005-1011 (Pubitemid 29233921)
29. Barbareschi M, Girlando S, Mauri FM, et al. Quantitative growth fraction evaluation with MIB1 and Ki67 antibodies in breast carcinomas. Am J Clin Pathol 1994;102:171-175 (Pubitemid 24320519)
30. Labat-Moleur F, Guillermet C, Lorimier P, et al. TUNEL apoptotic cell detection in tissue sections: critical evaluation and improvement. J Histochem Cytochem 1998;46:327-334 (Pubitemid 28117382)
31. Yang AS, Estecio MR, Doshi K, Kondo Y, Tajara EH, Issa JP. A simple method for estimating global DNA methylation using bisulfite PCR of repetitive DNA elements. Nucleic Acids Res 2004;32:e38.
32. Colella S, Shen L, Baggerly KA, Issa JP, Krahe R. Sensitive and quantitative universal Pyrosequencing methylation analysis of CpG sites. Biotechniques 2003;35:146-150 (Pubitemid 36828724)
33. Yang AS, Doshi KD, Choi SW, et al. DNA methylation changes after 5-aza-2′-deoxycytidine therapy in patients with leukemia. Cancer Res 2006;66:5495-5503 (Pubitemid 43844978)
34. Aparicio A, Eads CA, Leong LA, et al. Phase I trial of continuous infusion 5-aza-2′-deoxycytidine. Cancer Chemother Pharmacol 2003;51:231-239 (Pubitemid 36469953)
35. Schrump DS, Fischette MR, Nguyen DM, et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin Cancer Res 2006;12:5777-5785 (Pubitemid 44629609)
36. Issa JP. DNA methylation as a therapeutic target in cancer. Clin Cancer Res 2007;13:1634-1637 (Pubitemid 46952927)
37. Ishida S, Lee J, Thiele DJ, Herskowitz I. Uptake of the anticancer drug cisplatin mediated by the copper transporter Ctr1 in yeast and mammals. Proc Natl Acad Sci U S A 2002;99:14298-14302 (Pubitemid 35257666)
38. Pohlmann P, DiLeone LP, Cancella AI, et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am J Clin Oncol 2002;25:496-501. (Pubitemid 35154957)
39. Schwartsmann G, Schunemann H, Gorini CN, et al. A phase I trial of cisplatin plus decitabine, a new DNA-hypomethylating agent, in patients with advanced solid tumors and a follow-up early phase II evaluation in patients with inoperable non-small cell lung cancer. Invest New Drugs 2000;18:83-91. (Pubitemid 30175899)
40. Montero AJ, Diaz-Montero CM, Mao L, et al. Epigenetic inactivation of EGFR by CpG island hypermethylation in cancer. Cancer Biol Ther 2006;5:1494-1501 (Pubitemid 46256620)
41. Herbst RS, Prager D, Hermann R, et al. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005;23:5892-5899 (Pubitemid 46300205)
42. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial-INTACT 2. J Clin Oncol 2004;22:785-794 (Pubitemid 41103589)
43. Butts CA, Bodkin D, Middleman EL, et al. A. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 2007;25:5777-5784